Table 3.
Allele | FDA | CPIC | ICUR | Willingness-to-pay threshold | Type | Reference++ |
---|---|---|---|---|---|---|
MMRgenes | – | – | $26,000/QALY | $50,000/QALY | CE | (91) |
BRCA1/2 3 | – | – | $9,000/QALY | $50,000/QALY | CE | (Gavan et al., 2018) |
3BRCA1/2 testing is regarded as medically necessary only for patients with breast cancer and healthy individuals with a family history of breast cancer. ++Identification number of the article ( Supplementary Table 1 ).